Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer

Journal of Pathology

Volumn 196, Issue 3, 2002, Pages 266-274

  Paul, Pascale ^a   Carosella, Edgardo D ^a   Lefebvre, Sophie ^a   Uzan, Serge ^b   Antoine, Martine ^b   McMaster, Michael ^c   Dausset, Jean ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Breast cancer; HLA G; Immune escape; Killing inhibitory receptors; Tumour immunology

Indexed keywords

CD68 ANTIGEN; CD8 ANTIGEN; CELL RECEPTOR; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; LIGAND; PARAFFIN;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST BIOPSY; BREAST CANCER; CELL INFILTRATION; CELL INVASION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DECIDUA; EPITHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INFLAMMATION; NATURAL KILLER CELL; PREGNANCY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPHOBLAST; TUMOR IMMUNITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CD8-POSITIVE T-LYMPHOCYTES; EPITHELIAL CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0036184227     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1039     Document Type: Article

References (58)

1. HLA-G and HLA-E: Fundamental and pathophysiological aspects
2. NK cell recognition of non-classical HLA class I molecules
3. Cell-cell adhesion mediated by CD8 and human histocompatibility leucocyte antigen G, a non-classical major histocompatibility complex class I molecule on cytotrophoblasts
4. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha
5. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8
6. HLA-G inhibits the transendothelial migration of human NK cells
7. HLA-G inhibits the allogeneic proliferative response
8. HLA-G suppresses proliferation of CD4(+) T-lymphocytes
9. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA-G) bind to peripheral blood myelomonocytic cells
10. Presence of HLA-G-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines
11. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: Preferential response to an HLA-G-derived nonamer
12. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
13. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines
14. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes
15. Glucocorticoid hormones up-regulate levels of HLA-G transcripts in trophoblasts
16. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ
17. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells
18. Thrombin receptor overexpression in malignant and physiological invasion processes
19. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues
20. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes
21. Tumor antigens recognized by T cells
22. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
23. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege
24. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
25. The immunotolerance role of HLA-G
26. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance
27. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells
28. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies
29. HLA-G protein expression is not induced during malignant transformation
30. Modulation of HLA-G antigen expression by human cytomegalovirus: Specific induction in activated macrophages harboring human cytomegalovirus infection
31. Implication of HLA-G in heart graft acceptance
32. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions
33. HLA-G, -E, -F preworkshop: Tools and protocols for analysis of non-classical class I gene transcription and protein expression
34. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gamma IFN treatment
35. Expression of HLA G in human tumors is not a frequent event
36. HLA-G expression by tumors
37. Expression analysis of classic and non-classic HLA molecules before interferon alpha-2b treatment of melanoma
38. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
39. The origin and function of tumor-associated macrophages
40. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma
41. Where have all the T cells gone? Mechanisms of immune evasion by tumors
42. HLA-G expression in normal and malignant hematopoietic cells
43. Expression and regulation of HLA-G in human glioma cell lines
44. Modulation of HLA-G expression in human thymic and amniotic epithelial cells
45. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta
46. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis
47. Analysis of HLA-G expression in tumor cell lines
48. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells
49. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
50. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
51. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: Association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases
52. Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma
53. Regulation of KIR expression in human T cells: A safety mechanism that may impair protective T-cell responses
54. HLA-G expression in human melanoma cells: Protection from NK cytolysis
55. HLA-G mediated-inhibition of antigen-specific cytotoxic T lymphocytes
56. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions
57. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G
58. Biological therapies for breast carcinoma: Concepts for improvement in survival